Colin Bristow
Stock Analyst at UBS
(1.63)
# 3,309
Out of 5,182 analysts
106
Total ratings
40.32%
Success rate
-5.83%
Average return
Main Sectors:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBTX Nanobiotix | Maintains: Neutral | $3.5 → $30 | $31.16 | -3.72% | 1 | May 1, 2026 | |
| ENGN enGene Therapeutics | Maintains: Neutral | $4 → $10 | $7.61 | +31.41% | 3 | Nov 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $429.85 | +27.02% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $132.69 | -15.59% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $65.49 | +22.16% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $3.61 | +38.50% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $1.88 | -46.81% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $27.85 | -38.96% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $323.85 | -1.50% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $2.48 | +61.29% | 4 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $28 | $26.30 | +6.46% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $113.11 | +6.09% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $187.21 | +7.90% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.26 | +1,169.84% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $709.21 | +54.96% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $22.04 | +657.71% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $967.93 | -56.61% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $14.91 | -86.59% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.88 | +857.45% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $208.16 | -29.86% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $57.38 | +30.71% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $3.04 | +756.67% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $7.53 | +19.52% | 1 | Aug 23, 2021 |
Nanobiotix
May 1, 2026
Maintains: Neutral
Price Target: $3.5 → $30
Current: $31.16
Upside: -3.72%
enGene Therapeutics
Nov 12, 2025
Maintains: Neutral
Price Target: $4 → $10
Current: $7.61
Upside: +31.41%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $429.85
Upside: +27.02%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $132.69
Upside: -15.59%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $65.49
Upside: +22.16%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $3.61
Upside: +38.50%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $1.88
Upside: -46.81%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $27.85
Upside: -38.96%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $323.85
Upside: -1.50%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $2.48
Upside: +61.29%
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $26.30
Upside: +6.46%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $113.11
Upside: +6.09%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $187.21
Upside: +7.90%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.26
Upside: +1,169.84%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $709.21
Upside: +54.96%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $22.04
Upside: +657.71%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $967.93
Upside: -56.61%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $14.91
Upside: -86.59%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $1.88
Upside: +857.45%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $208.16
Upside: -29.86%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $57.38
Upside: +30.71%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $3.04
Upside: +756.67%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $7.53
Upside: +19.52%